These findings that FAP α τ-MT breaks tumor immune tolerance as a local IDO inhibitor, suggesting that conjugation of 1-MT to a tumor antigen peptide is a potentially effective clinical cancer immunotherapy. The gene discussed is FAP; the disease is neoplasm.